Bicara Therapeutics Analyst Price Targets

Wall Street analyst price targets and consensus rating for Bicara Therapeutics (BCAX).

Price Target Range — 9 Quarters

Analyst Consensus — 14 Analysts

1S.Buy

11Buy

1Hold

1Sell

Consensus RatingBuy# Analysts14Avg. Consensus PT$31Upside to Avg. PT+236.0%

Rating Trend — Last 9 Months

Recent Analyst Actions

See all ratings →

Date	Firm	Analyst	Action	Rating Change	Price Target
Oct 30, 2026	Goldman Sachs	Richard Law	Downgrade	Neutral→Sell	$20→$8
Oct 29, 2026	Wedbush	David Nierengarten	PT Cut	Outperform	$33→$24
Oct 19, 2026	BTIG	Jeet Mukherjee	Maintained	Buy	$39
Aug 19, 2026	BMO Capital	David Lebowitz	Initiate	Outperform	$35
Aug 12, 2026	Goldman Sachs	Richard Law	PT Raise	Neutral	$18→$20
Aug 12, 2026	Wedbush	David Nierengarten	PT Raise	Outperform	$30→$33
Aug 12, 2026	Morgan Stanley	Judah Frommer	PT Raise	Overweight	$37→$39
Aug 12, 2026	Mizuho	Joseph Catanzaro	PT Raise	Neutral	$18→$20
Aug 12, 2026	Wells Fargo	Eva Fortea Verdejo	PT Raise	Equal-Weight	$16→$23
Aug 12, 2026	BTIG	Jeet Mukherjee	PT Raise	Buy	$28→$39
May 12, 2026	Goldman Sachs	Richard Law	PT Raise	Neutral	$16→$18
May 12, 2026	Morgan Stanley	Judah Frommer	PT Raise	Overweight	$36→$37
May 11, 2026	Guggenheim	Brad Canino	Initiate	Buy	$42
Mar 31, 2026	Goldman Sachs	Richard Law	PT Raise	Neutral	$14→$16
Mar 31, 2026	Wedbush	David Nierengarten	Maintained	Outperform	$30
Mar 31, 2026	Wells Fargo	Eva Fortea Verdejo	PT Raise	Equal-Weight	$11→$16
Mar 31, 2026	Citizens	Reni J. Benjamin	Maintained	Market Outperform	$31
Mar 31, 2026	HC Wainwright & Co.	Robert Burns	PT Raise	Buy	$40→$42
Mar 25, 2026	B of A Securities	Tazeen Ahmad	Initiate	Buy	$35
Jan 29, 2026	Citizens	Reni J. Benjamin	Initiate	Market Outperform	$31

Analyst Ratings News

PRO
Goldman Sachs Downgrades Bicara Therapeutics to Sell, Lowers Price Target to $8

Goldman Sachs analyst Richard Law downgrades Bicara Therapeutics (NASDAQ:BCAX) from Neutral to Sell and lowers the price target from $20 to $8.

Benzinga Newsdesk

PRO
Wedbush Maintains Outperform on Bicara Therapeutics, Lowers Price Target to $24

Wedbush analyst David Nierengarten maintains Bicara Therapeutics (NASDAQ:BCAX) with a Outperform and lowers the price target from $33 to $24.

Benzinga Newsdesk

PRO
BTIG Reiterates Buy on Bicara Therapeutics, Maintains $39 Price Target

BTIG analyst Jeet Mukherjee reiterates Bicara Therapeutics (NASDAQ:BCAX) with a Buy and maintains $39 price target.

Benzinga Newsdesk

PRO
BMO Capital Initiates Coverage On Bicara Therapeutics with Outperform Rating, Announces Price Target of $35

BMO Capital analyst David Lebowitz initiates coverage on Bicara Therapeutics (NASDAQ:BCAX) with a Outperform rating and announces Price Target of $35.

Benzinga Newsdesk

PRO
Goldman Sachs Maintains Neutral on Bicara Therapeutics, Raises Price Target to $20

Goldman Sachs analyst Richard Law maintains Bicara Therapeutics (NASDAQ:BCAX) with a Neutral and raises the price target from $18 to $20.

Benzinga Newsdesk

PRO
Wedbush Maintains Outperform on Bicara Therapeutics, Raises Price Target to $33

Wedbush analyst David Nierengarten maintains Bicara Therapeutics (NASDAQ:BCAX) with a Outperform and raises the price target from $30 to $33.

Benzinga Newsdesk

Bicara Therapeutics Inc

Bicara Therapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
Goldman Sachs Downgrades Bicara Therapeutics to Sell, Lowers Price Target to $8

PRO
Wedbush Maintains Outperform on Bicara Therapeutics, Lowers Price Target to $24

PRO
BTIG Reiterates Buy on Bicara Therapeutics, Maintains $39 Price Target

PRO
BMO Capital Initiates Coverage On Bicara Therapeutics with Outperform Rating, Announces Price Target of $35

PRO
Goldman Sachs Maintains Neutral on Bicara Therapeutics, Raises Price Target to $20

PRO
Wedbush Maintains Outperform on Bicara Therapeutics, Raises Price Target to $33

People Also Watch

People Also Watch

Bicara Therapeutics Inc

Bicara Therapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROGoldman Sachs Downgrades Bicara Therapeutics to Sell, Lowers Price Target to $8

PROWedbush Maintains Outperform on Bicara Therapeutics, Lowers Price Target to $24

PROBTIG Reiterates Buy on Bicara Therapeutics, Maintains $39 Price Target

PROBMO Capital Initiates Coverage On Bicara Therapeutics with Outperform Rating, Announces Price Target of $35

PROGoldman Sachs Maintains Neutral on Bicara Therapeutics, Raises Price Target to $20

PROWedbush Maintains Outperform on Bicara Therapeutics, Raises Price Target to $33

People Also Watch

People Also Watch

PRO
Goldman Sachs Downgrades Bicara Therapeutics to Sell, Lowers Price Target to $8

PRO
Wedbush Maintains Outperform on Bicara Therapeutics, Lowers Price Target to $24

PRO
BTIG Reiterates Buy on Bicara Therapeutics, Maintains $39 Price Target

PRO
BMO Capital Initiates Coverage On Bicara Therapeutics with Outperform Rating, Announces Price Target of $35

PRO
Goldman Sachs Maintains Neutral on Bicara Therapeutics, Raises Price Target to $20

PRO
Wedbush Maintains Outperform on Bicara Therapeutics, Raises Price Target to $33